Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / Enanta Pharma, AbbVie  >>  Phase 3
Welcome,         Profile    Billing    Logout  

17 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma
SAPPHIRE-I, NCT01716585 / 2012-002019-25: A Study to Evaluate Chronic Hepatitis C Infection

Checkmark PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II
Nov 2014 - Nov 2014: PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II
Checkmark EASL 2014: SAPPHIRE-I
Apr 2014 - Apr 2014: EASL 2014: SAPPHIRE-I
Checkmark SAPPHIRE-I
More
Completed
3
636
NA
ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin, Placebo for ABT-450/r/ABT-267, Placebo for ABT-333, Placebo for ribavirin
AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C Infection
10/13
10/14
NCT01715415 / 2012-002035-29: A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Checkmark PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II
Nov 2014 - Nov 2014: PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II
Checkmark SAPPHIRE-II
Apr 2014 - Apr 2014: SAPPHIRE-II
Checkmark DDW 2014: SAPPHIRE-II
More
Completed
3
395
NA
ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin, Placebo for ABT-450/r/ABT-267, Placebo for ABT-333, Placebo for ribavirin
AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C Infection
11/13
10/14
PEARL-III, NCT01767116 / 2012-003687-52: A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection

Checkmark PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II
Nov 2014 - Nov 2014: PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II
Checkmark ACG 2014 - PEARL-II and PEARL-III
Sep 2014 - Sep 2014: ACG 2014 - PEARL-II and PEARL-III
Checkmark ICAAC 2014 - PEARL-II and PEARL-III
More
Completed
3
419
NA
ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin, Placebo for ribavirin
AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C Infection
12/13
08/14
PEARL-IV, NCT01833533 / 2012-005522-29: A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

Checkmark PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II
Nov 2014 - Nov 2014: PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II
Checkmark AASLD 2014: PEARL IV
Oct 2014 - Oct 2014: AASLD 2014: PEARL IV
Checkmark PEARL III & PEARL IV
More
Completed
3
305
NA
ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin, Placebo for Ribavirin
AbbVie
Chronic Hepatitis C Infection
12/13
09/14
PEARL-II, NCT01674725 / 2011-005740-95: A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C

Checkmark PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II
Nov 2014 - Nov 2014: PEARL-I, PEARL-II, PEARL-III, PEARL-IV, SAPHIRE-I, SAPHIRE-II
Checkmark ACG 2014 - PEARL-II and PEARL-III
Sep 2014 - Sep 2014: ACG 2014 - PEARL-II and PEARL-III
Checkmark ICAAC 2014 - PEARL-II and PEARL-III
More
Completed
3
187
NA
ABT-450/r/ABT-267, ABT-333, ABT-450 also known as paritaprevir, ABT-267 also known as ombitasvir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin
AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C Infection
01/14
10/14
TURQUOISE-II, NCT01704755 / 2012-003088-23: A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis

Checkmark AGW 2014
Oct 2014 - Oct 2014: AGW 2014
Checkmark UEGW 2014: TURQUOISE-II
Oct 2014 - Oct 2014: UEGW 2014: TURQUOISE-II
Checkmark AASLD 2014: TURQUOISE-II
More
Completed
3
381
NA
ABT-450/r/ABT-267, ABT-333, Viekira Pak; ABT-450 also known as paritaprevir; ABT-267 also known as ombitasvir; ABT-333 also known as dasabuvir, Ribavirin (RBV)
AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C Infection, Compensated Cirrhosis
01/14
09/14
MALACHITE 1, NCT01854697 / 2012-003754-84: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

Checkmark DDW 2015
May 2015 - May 2015: DDW 2015
Completed
3
311
NA
ABT-450/r/ABT-267, ABT-333, Viekira Pak, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Holkira Pak, Ribavirin, Telaprevir, Pegylated Interferon alpha 2-a (PegIFN)
AbbVie
Chronic Hepatitis C Infection
11/14
07/15
MALACHITE II, NCT01854528 / 2012-003738-18: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults

Checkmark DDW 2015
May 2015 - May 2015: DDW 2015
Completed
3
148
NA
ABT-450/r/ABT-267, ABT-333, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ABT-333 also known as dasabuvir, Viekira PAK, Ribavirin, Pegylated Interferon a-2a (PegINF), Telaprevir
AbbVie
Chronic Hepatitis C Infection
11/14
07/15
NCT02442271: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

Completed
3
222
NA
ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, ribavirin
AbbVie
Chronic Hepatitis C Infection
07/16
09/16
NCT02442284: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection

Completed
3
99
NA
ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, Ribavirin
AbbVie
Chronic Hepatitis C, Cirrhosis, Hepatitis C Virus
08/16
10/16
GEODE - I, NCT02504099 / 2015-001049-10: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

Terminated
3
3
NA
ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, ombitasvir/paritaprevir/ritonavir, Technivie, ribavirin
AbbVie
Chronic Hepatitis C Infection
09/16
12/16
NCT02517515: ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection

Completed
3
650
NA
ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
AbbVie
Hepatitis C Virus (HCV)
10/16
06/17
GEODE II, NCT02609659: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

Completed
3
105
NA
ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, ribavirin
AbbVie
Hepatitis C Virus (HCV)
10/16
12/16
NCT02487199 / 2015-002012-33: Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Completed
3
18
NA
ombitasvir/paritaprevir/ritonavir and dasabuvir, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, ombitasvir/paritaprevir/ritonavir, Technivie, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267
AbbVie
Hepatitis C Virus (HCV)
12/16
12/16
NCT02207088: Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Completed
3
68
NA
ombitasvir/paritaprevir/ritonavir, ABT-450/r/ABT-267, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, dasabuvir, ABT-333, Ribavirin, RBV
AbbVie
Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis, Severe Renal Impairment, End-stage Renal Disease
12/16
12/16
TARGET3D, NCT02634008: Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Completed
3
83
Europe, RoW
Paritaprevir/ritonavir/ombitasvir, Viekira Pak, Dasabuvir, Ribavirin, Glecaprevir/pibrentasvir
Kirby Institute, AbbVie
Hepatitis C, Acute
04/21
04/21
DASCO, NCT02555943: DAAs Treatment for Chronic HCV/HBV Co-infection Patients

Completed
2/3
23
RoW
Ledipasvir/Sofosbuvir, Harvoni®, GS-7977, GS-5885, Sofosbuvir and Daclatasvir, Sovaldi®, GS-7977, Daklinza®,BMS-790052, Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, VIEKIRA PAK™, Entecavir, BARACLUDE®, Tenofovir disoproxil, VIREAD®
Humanity and Health Research Centre, Beijing 302 Hospital, Nanfang Hospital of Southern Medical University
Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation
05/21
08/21

Download Options